Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide

Neuropsychiatric Complaints in Graves' patients



by Robert A. Stern, Ph.D.; Boykin Robinson; Anna R. Thorner; James E. Arruda, Ph.D.; Mark L. Prohaska, Ph.D.; Arthur J. Prange, Jr., M.D.

One hundred thirty-seven patients with treated Graves’ disease completed a questionnaire pertaining to neuropsychiatric complaints. Psychiatric symptoms, especially anxiety and irritability, were common prior to treatment of hyperthyroidism. These complaints appeared to result in delays in seeking treatment as well as delays in receiving appropriate diagnosis. Subjects reported significantly worse memory, attention, Planning and productivity while hyperthyroid than prior to becoming hyperthyroid, and, although somewhat improved once euthyroid, they reported residual cognitive deficits. These results suggest that neuropsychiatric impairments are highly prevalent in Graves’ disease, may lead to initial misdiagnosis or delays in diagnosis of the endocrine disorder, and may continue even once patients are believed to be euthyroid.

 (The Journal of Neuropsychiatry and Clinical Neurosciences 1996; 8:181-185)

Disorders of the hypothalamic- pituitary-thyroid axis are often associated with neuropsychiatric impairments.1 The presenting symptoms of Graves’ disease, the most common cause of hyperthyroidism, are frequently psychiatric in nature, leading to possible difficulties in the differential diagnosis of hyperthyroidism and anxiety disorder. 2 Although many of the somatic symptoms of anxiety (such as tachycardia and tremor) may be caused by increased peripheral sympathetic tone secondary to thyrotoxicosis, several studies have suggested that additional psychiatric and cognitive impairments are also seen in hyperthyroid patients.3-10 These findings suggest a possible central effect, either due to alterations of brain thyroid hormone homeostasis or, perhaps, to autoimmune involvement in the brain.

The prevalence of neuropsychiatric impairments in Graves’ disease is unknown because previous studies, which have had small sample sizes, have not addressed the issue of prevalence. Furthermore, although clinical endocrinologists acknowledge that psychiatric and cognitive complaints are common in patients with Graves’ disease, there have been no studies addressing the possible impact of these complaints on initial diagnosis and treatment. Finally, it is unclear whether the neuropsychiatric difficulties in Graves’ disease follow a course parallel to the resolution of thyrotoxicosis5-11 or remain after euthyroidism has been achieved.9-12

In this report, we present the results of a survey of the patient membership of the National Graves’ Disease Foundation. The questionnaire addressed issues pertaining to the initial diagnosis and treatment of Graves’ disease, the nature and extent of the psychiatric, somatic, and cognitive complaints of respondents when they were hyperthyroid, and assessment of residual complaints. This represents the first largescale survey study of neuropsychiatric functioning in patients with Graves’ disease.

Methods

An anonymous paper-and pencil questionnaire was sent to all 240 patient members of the National Graves’ Disease Foundation in March 1992. A cover letter describing the confidentiality and anonymity of the material was included, as was a postage-paid envelope to be used for returning the completed questionnaire. The questionnaire consisted of 24 items designed to assess pertinent demographic, diagnostic, and disease process information, as well as the neurocognitive and emotional functioning of the respondents. Development of items was guided by advice from the National Graves’ Disease Foundation and the findings of previous empirical studies of neuropsychiatric functioning in Graves’ disease.2-5 One section focused on the length of time it took patients to seek treatment after the symptoms initially appeared and to be diagnosed after seeking help. To gain information on changes in psychiatric symptoms that could be related to Graves’ thyrotoxicosis, a number of questions were asked regarding psychiatric referrals, diagnoses, and medications before and after the onset of Graves’ disease. An extensive self-report section of symptoms experienced while hyperthyroid and after receiving treatment was designed to track common symptoms in an acute hyperthyroid state as well as residual symptoms after euthyroidism was achieved. Visual analogue scales 100 mm in length with “good” and “poor” poles were created to measure subjective reports of neuropsychological functioning (memory, attention, planning, and productivity) before, during, and after the onset of Graves’ symptoms.

Results

Of the 240 questionnaires distributed, 170 (70.8%) were returned. Of these, 33 were excluded because of one or more of the following: incomplete material, the presence of coexisting debilitating illnesses (such as muscular dystrophy or multiple sclerosis), disease onset that occurred either before age 21 or after age 65, or lack of a specific diagnosis of Graves’ hyperthyroidism. There were then 137 eligible completed questionnaires. Of these, 127 (92.7%) were completed by women, and 10 (7.3%) were completed by men, with an age range of 21 to 78 years (mean SD = 48.1 ± 11.5). The gender and age distributions in this sample are similar to those seen in Graves’ disease in the general population.13,14 Table 1 presents pertinent demographic information of the sample.

TABLE 1. Demographic characteristics

Characteristicn%GenderFemal12792.7Male107.3Marital StatusSingle2417.8Married7656.3Divorced813.3Separated21.5Never Married32.2Living w/other128.9Employment StatusFull-time7151.8Part-time2115.3Student32.2Homemaker2316.8Disabled1410.2Unemployed or looking53.6Income level<$25,0002719.9$25,000-$50,0005439.7$50,000-$75,0002619.1$75,000-$100,000128.8$100,000-$250,000139.6>$250,00042.9Education levelNo high school diploma21.5High School diploma or GED4331.6College/Technical4835.6Master's2115.4Doctorate85.9Other1410.3

 

Results of the questionnaire indicate that only 15% of subjects sought treatment for Graves’ disease symptoms within 1 month of initially experiencing the symptoms. In contrast, approximately 35% of respondents reported taking 6 months or more from the onset of Graves’ symptoms to the time they sought treatment (Table 2). Approximately 35% of respondents reported that more than 3 months passed between the time they first sought treatment and the time they received an accurate diagnosis of Graves’ disease (Table 3).

TABLE 2. Duration of time between first experiencing symptoms and seeking treatment

Durationn%%(Cumulative)[a]Less than 1 month2014.9100.01-3 months3626.985.13-6 months3123.158.26 months to 1 year2115.735.1More than 1 year2619.419.4

Note: Total n = 134; data not provided by 3 subjects.

[a]Percentage waiting this long or longer to seek treatment.

TABLE 3. Duration of time beween first seeking treatment and receiving Graves’ diagnosis

Durationn%%(Cumulative)[a]Less than 1 week4130.2100.01 week to 1 month3122.869.91-3 months1712.547.13-6 months2014.734.6More than 6 months2719.919.9

Note: Total n = 136; data not provided by 1 subject.

[a]Percentage waiting this long or longer to receive diagnosis.

A variety of psychiatric symptoms were endorsed as being present while respondents were hyperthyroid. As shown in Table 4, the most common of these symptoms included irritability (78.1%), anxious mood (72.3%), anger (55.9%), and crying (55.1%). In addition, other signs and symptoms that are easily attributable to hyperthyroidism but are also cardinal features of psychiatric illness were frequently endorsed, such as insomnia (66.4%), fatigue (65.7%), weight loss (62.8%), sensation of shakiness (65.4%), and shortness of breath (59.6%). Furthermore, only 7.7% of respondents reported ever being prescribed psychotropic medications prior to the 2 years before the onset of symptoms for Graves’ disease, but 33.1% reported being prescribed psychotropic medications after being diagnosed with Graves’ disease.

TABLE 4. Prevalence of symptoms while respondents were hyperthyroid

Symptomn%Irritability10778.1Visible Shakiness (especially in hands106787.4Feeling hot most of the time10173.7Anxiety9972.3Inability to sleep9166.4Increased fatigue/weakness9065.7Sensation of shakiness inside (but not visible)8965.4Loss of more than 5 pounds in 3 months8662.8Trouble breathing/shortness of breath8159.6Change in hair or skin texture (e.g., dryness)7857.4Anger7655.9Increased crying7555.1Easily startled7252.9Inability to perform some daily tasks6850.0Hot or cold flashes6547.8Tired all the time6547.4Significant decrease in social activity6245.6Feelings of being out of control6144.5Hopelessness5842.6Sadness5741.9Loss of sense of humor5641.2Decreased sexual desire5540.1Slowed thinking ability5439.7Loss of interest in things that formaly gave you pleasure5339.0Chest pain5137.5Not being able to "connect" with others4633.8Changes in menstrual cycle/Impotence4633.8

Table 5. Means and standard deviations for memory, attention, planning, and productivity visual analogue scales

 

ScalePre-HyperthyroidHyperthyroidCurrentlyFaMemory77.68 ± 18.1847.56 ± 31.2355.39 ± 25.9369.77Attention74.75 ± 20.5940.36 ± 29.3955.76 ± 25.1480.88Planning75.06 ± 19.9745.66 ± 29.9360.11 ± 25.0961.95Productivity76.31 ± 19.1441.99 ± 31.5355.79 ± 25.7273.55

 

Note: All scales had possible range of 0-100, with higher scores representing better perceived functioning. aMain effects tested with repeated-measures analyses of variance. All resulting Fs were significant, P<0.001. Post hoc pairwise comparisons were performed by using Tukey’s honestly significant difference test; all were significant, P<0.001.

For all areas of functioning assessed on the self-report visual analogue scales, subjects reported significantly worse functioning while hyperthyroid compared with the 2 years prior to the onset of hyperthyroid symptoms. Respondents reported that their current functioning, although better than during the hyperthyroid period, was significantly worse than during the premorbid time period (Table 5).

At the end of the questionnaire, there was a small space for any additional written comments the respondents wished to make. Surprisingly, 84% of the respondents used this space. In an attempt to quantify these written comments, we defined four areas of content, including 1) cognitive functioning, 2) mood or emotional functioning, 3) somatic complaints, and 4) complaints about medical care. Of the subjects who provided written comments, 24% described problems in cognitive functioning, most commonly involving slowed mental functioning and memory difficulties; 37% described altered mood or personality, most commonly involving depression, mood swings, and feelings of anxiety, panic, and worry; 50% reported having some physical symptoms, most commonly those related to eye disease (such as exophthalmos); and 11% described problems they have faced with their medical care related to Graves’ disease, with the most common involving anger at the delay in diagnosis and complaints that their physicians either did not believe them or did not understand their symptoms. In many cases, subjects included a detailed history such as the following:

Before I was diagnosed I felt as though I was losing my mind. I couldn’t get along well with others and my marriage was affected. I would go to the family doctor and he would say, “Oh, this is normal for a working mother of 3.” I lost all selfconfidence and worried a lot. I thought I had cancer or some other life-threatening disease. When I found a doctor that I was able to talk to and she understood, it was a wonderful moment!

Discussion

This report represents the first large-scale survey of the neuropsychiatric symptoms associated with Graves’ hyperthyroidism. Results indicate that psychiatric symptoms are very common in the early presentation of Graves’ disease and involve many of the mood and somatic features found in primary psychiatric illness, including anxiety, irritability, insomnia, anorexia, fatigue, dysphoria, hopelessness, and anger. These symptoms are severe enough that approximately one-third of the respondents reported being prescribed psychotropic medications after their diagnosis of Graves’ disease. With regard to cognitive functioning, respondents reported a significant decline in memory, attention, planning, and overall productivity from the time period 2 years prior to Graves’ symptom onset to the period when hyperthyroid. It is noteworthy that although subjects reported their cognitive functioning was improved relative to the hyperthyroid period, they felt that their current functioning still was worse than it was prior to the onset of the disease.

A striking secondary finding of this study was that 84% of the respondents provided written comments describing their history of Graves’ disease. These descriptions may shed some light on the findings that the majority of subjects waited more than 3 months before seeking medical help for their Graves’-related symptoms and that for almost half of the respondents it took more than 1 month to receive an accurate diagnosis after first seeking help. Many of the initial symptoms of Graves’ disease are not at all specific to the illness. In fact, as reported in previous studies2,14 and further supported by the results of this study, neuropsychiatric complaints can be the presenting symptoms of Graves’ disease. Many patients who first experience these symptoms (such as irritability, anxiety, fatigue, or weight loss) may hesitate to seek medical help because they believe they are merely experiencing temporary anxiety or are embarrassed to seek help for such Personal” problems. Unfortunately, it appears that some health care providers (and mental health care providers, who may first see these patients) too quickly dismiss the symptoms as representing primary psychiatric disorders rather than manifestations of the underlying endocrinopathy.

The neuropsychiatric impairments associated with Graves’ disease not only have dramatic effects on the patient, but also frequently affect the patient’s support system. The psychiatric, cognitive, and personality changes that occur with this illness can produce significant marital stress and conflict, as described in a recent open letter to the spouses of Graves’ patients that appeared in the National Graves’ Disease Foundation’s newsletter:

In a lot of ways my wife and I were fortunate. She was diagnosed with Graves’ disease after approximately nine months; at least that is the closest she and I can pinpoint when she began to first experience the symptoms we now associate with Graves’. During that time, however, while I always knew my wife loved me, frequently who I was married to was not my wife. one aspect was the mood swings, the unexpected outbursts of anger and accusation, the unexplainable crying. This took the most work for me to deal with emotionally.15

The survey format of this study allowed for a relatively large sample to be assessed. Moreover, the anonymity of the questionnaire probably contributed to the very high return rate and the many open-ended written responses. However, there are several limitations to this design that may hamper the generalizability and overall interpretation of the findings. By definition, this format relies on retrospective recall and subjective report of psychiatric and cognitive symptoms; both of these modes are potentially highly unreliable and may result in artificial inflation of symptom reports. Retrospective recall of the timing of symptom onset is also of questionable reliability, ant there was no objective verification of the length of time between first seeking medical help and accurate diagnosis. The anonymity of the questionnaire also precludes verification of Graves’ diagnosis or the obtaining of thyroid hormone levels. There may also be sample bias due to the use of the membership of the National Graves’ Disease Foundation; that is, those individuals who seek out membership in such an organization may have very different neuropsychiatric profiles (both before and after onset of Graves’ disease) from other Graves’ patients not belonging to this kind of organization. Furthermore, although there was an extremely high response rate, it is still possible that these data are not truly representative even of the entire membership of the Foundation. To address these limitations, a large-scale, longitudinal, prospective, objective neuropsychiatric study of newly diagnosed Graves’ patients would be necessary.

Even if the results of the present study are conservatively interpreted, it appears that neuropsychiatric symptoms are common in Graves’ disease, may continue even after peripheral euthyroidism has been achieved, may lead to difficulties in differential diagnosis, and represent a significant area of morbidity and stress associated with this autoimmunerelated endocrine disorder. Involvement of mental health care providers who are familiar with neuropsychiatric differential diagnostic issues should prove helpful in the management of patients with Graves’ disease, both at initial presentation and later in the course of illness.

Download as a PDF.

The authors gratefully acknowledge the helpful contributions of Dr. Nancy Patterson, Dr. Susan G. Silva, and Ms. Elizabeth Singer, and the support of the National Graves’ Disease Foundation. This study was supported in part by National Institute of Mental Health Grants MH33127 and MH22536.

Received February 22, 1995; revised May 2,1995; accepted May 17,1995. From the Departments of Psychiatry and Human Behavior and Clinical Neurosciences, Brown University School of Medicine, Providence Rhode Island; and the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill. Address correspondence to Dr. Stern, Neurobehavioral Research, Department of Psychiatry, Rhode Island Hospital, 593 Eddy Street Providence, Rl 02903. Copyright © 1996 Americian Psychiatric Press, Inc.

Reprinted with permission of: The Journal of Neuropsychiatry and Clinical Neurosciences, Washington, D.C. and Robert A. Stern, Ph.D.; NGDF Advisory Board Member

1. Stern, R.A., Prange A.J. Neuropsychiatric aspects of endocrine disorders, in Comprehensive Textbook of Psychiatry., edited by Kaplan H.I., Sadock B.J. Baltimore, Williams and Wilkins, i995, pp 241-251

2. Kathol R.G., Delahunt J.W. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen Hosp Psychiatry 1986; 8:23 28

3. MacCrimmon D.J., Wallace J.E., Goldberg W.M., et al Emotional disturbance and cognitive deficits in hyperthyroidism. Psychosom Med 1979; 41:331-340

4. Trzepacz P.T., McCue M., Klein I., et al A psychiatric and neuropsychological study of patients with untreated Graves’ disease. Gen Hosp Psychiatry 1988,10:49-55

5. Kathol R.G., Tumer R., Delahunt J. Depression and anxiety associated with hyperthyroidism: response to antithyroid therapy. Psychosomatics 1986; 27:501-505

6. Palacois A., Cohen M.A.A., Cobbs R. Apathetic hyperthyroidism in middle age. Int J Psychiatry Med 1991; 21:393 400

7 Whybrow P.C., Prange A.J. Jr., Treadway C.R. Mental changes accompanying thyroid gland dysfunction. Arch Gen Psychiatry 1969; 20:48 63

8. Kronfol Z., Greden J.F., Conton M., et al Application of biological markers in depression secondary to thyrotoxicosis. Am J Psychiatry 1982; 139:13191322

 9. Bommer M., Eversmann T., Pickardt R., et al Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidis. Klinische Wochen-schrift 1990; 68:552-558

10. Stern R.A., Morey C.E., Perry J.R., et al Neuropsychological and psychiatric correlates of hyperthyroidism: preliminary fmdings (abstract) NeuroEndocrinology Letters 1990 12:273

11. Paschke R., Harsch I., Schlote B., et al Sequential psychological testing during the course of autoimmune hyperthyroidis. Klinische Wochen-schnft 1990; 68:942-950

12. Perrild H., Hansen J.M., Arnung K., et al Intellectual impairment after hyperthyroidism. Acta Endocrinologica 1986, 112.185-191

13. DeGroot L.J., Larsen P.R., Refetoff S., et al The Thyroid and its Diseases, 5th edition. New York, Wiley, 1984

14. Volpé, R. Graves’ disease, in The Thyroid: A Fundamental and Clinical Text edited by Braverman L.E., Utiger R.D., Philadelphia, J.B. Lippincott 1991, pp 648-657

 15. Boss, D. An open letter to the husbands of Graves’ disease patients. National Graves’ Disease Foundation News 1994, Summer

Recent News

Recent Forum Posts

  • Orbital Decompression

    May 24, 2017, 2:43 p.m.

    I'll just throw my oar in here in case it helps. I have had bilateral OD, and was taking methimazole when I...

  • Orbital Decompression

    May 24, 2017, 1:25 p.m.

    Kimberly - How long have you been off of the methimazole? I am assuming you are in remission?

  • Orbital Decompression

    May 24, 2017, 1:23 p.m.

    Thank you both. Dr. Douglas is great. I just skyped with him. He told me ultimately I will need to have the...

  • GD with TED

    May 23, 2017, 5:47 p.m.

    Update, Saw my eye Dr and he is pleased with my numbers upon measuring my eyes. I have more movement from...

  • Orbital Decompression

    May 23, 2017, 3:45 p.m.

    Dr Douglas did my decompressions. My first experience with general anesthesia was my thyroidectomy. That...

  • Orbital Decompression

    May 23, 2017, 2:40 p.m.

    Hello - Hopefully, Liz1967 will chime in here. I can tell you that I had a surgery (unrelated to Graves')...

  • Orbital Decompression

    May 23, 2017, 7:22 a.m.

    I wanted to update you. I have a consultation with Dr. Douglas tomorrow at 4:00. I also got to read my CT...

  • Tests Are Normal but I Don't Feel It

    May 22, 2017, 3:47 p.m.

    Hello - Hopefully, you have a copy of your lab results so that you can check the reference range for...

  • Login Issues? Try Clearing Your Browser History and Restart

    May 22, 2017, 3:43 p.m.

    bumping&#8230;again&#8230;

  • Tests Are Normal but I Don't Feel It

    May 22, 2017, 1:35 p.m.

    Two weeks ago I had my 3 month checkup on my TSH (1.07) and Free T4 (.9). I was diagnosed 2 years ago,...

  • Updated Post: Registration is LIVE for San Diego Event on June 10th!

    May 19, 2017, 9:45 a.m.

    Registration is now LIVE for our San Diego event on June 10th at UC San Diego Shiley Eye Institute! The event...

  • Men With Graves’ and TED

    May 15, 2017, 11:01 a.m.

    Hi Jill - Sorry I missed this post! You might also consider posting this on the main forum with the subject...

  • Breakthrough Treatment for Thyroid Eye Disease!

    May 11, 2017, 10:10 a.m.

    Hi all - Dr. Raymond Douglas is on Facebook LIVE right now discussing results from a breakthrough trial for a...

  • GD with TED

    May 7, 2017, 6:09 a.m.

    Things do get better. I am finally on the &ldquo;other side&rdquo;, all corrective surgery done, and back to...

  • GD with TED

    May 6, 2017, 2:55 p.m.

    Thanks for posting your progress, gives us all a sense of hope that things will get better!! So happy for...

Questions? Problems? Please contact us at info@ngdf.org or 877-643-3123.

GDATF on Facebook

Support the GDATF and become a member today!

© 2017 Graves' Disease & Thyroid Foundation